Navigation Links
Suicide - Aboriginal Communities Take Stock of the Killing Numbers

An international meeting organized to thrash out issues pertaining to indigenous child healthcare was a valuable //opportunity to focus attention on a burning issue - high rate of suicide amongst aboriginal communities. Amongst the Inuit population of Nunavik, Canada, the suicide rate stands at an all time high of seven times the national rate- 11.3 per thousand people.

Policymakers have been frowned upon for their lack of attention on child issues. Most of the hospitals do not look beyond immunization programs. What about special services to autistic children or those suffering cerebral palsy?

Although it is worthwhile to pool into the resources available within the community and fall back on the innate cultural strength, yet considering the magnitude of the problem, this is inadequate to make an effective impact on the suicide rate. External assistance is absolutely essential to make a significant impact on the killing numbers.

The exact numbers of suicides is shocking to say the least. In the Inuit office within Health Canada the suicide rate is almost 11 times the Canadian average. Mr. Simon, Canada’s leading aboriginal diplomat and a former president of the Inuit Circumpolar Conference, said, “The numbers speak for the issue; it should be considered an epidemic. It always overshadows the communities, even the healthy communities.”

According to experts, the reasons for the increase in suicides are many. Some of the major reasons are dull economy, employment issues, drug and alcohol abuse, sexual abuse and issues pertaining to mental health. With each community battling its own set of problems, it becomes imperative to train counselors according to the need rather than adopting a universal solution. Perhaps the right approach should begin by having appropriate people take charge of the counseling centers. Next step could be to improve the diagnostic centers.

An agreement has been signed between the In
'"/>




Page: 1 2

Related medicine news :

1. Suicide risk in panic disorder
2. Suicide risk high in 12-17 Age Group
3. Suicide might be inherited
4. Suicide reduced by anti-depressants
5. Twins Less Prone to Suicide Than Others
6. Suicide Prevention Program – Having its Intended Effec
7. Anxiety Can Increase The Risk Of Attempting Suicide In Men
8. Suicide Rate Amongst Male Prisoners Of UK Is Quite High
9. Aspirin induces Cancer Cells To Commit Suicide
10. More Youth In Himachal Resort To Suicide
11. Group Suicides On The Rise In Japan
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...ssibility of adverse effects with the use of the n...s.// A new study that is set to appear in this mo...on has cautioned on the use of the new group of dr...developed for the treatment of osteoporosis. They ...
...y pressure to resolve apparent obstructive sleep a...cording to researchers.// Timothy Morgenthaler, M...in the Sept. 1 issue of Sleep reports that complex...t to lose sleep from a combination of physical and...
...ologists in New Zealand has led the Hawkes Bay dis...logists worldwide; a scheme being tried out for th...og of undiagnosed medical reports. The medical cou...overseas radiologists are not registered under the...
...n E intake by mothers during pregnancy may heighte... Graham Devereux, of the department of environment...Aberdeen, Scotland and his team conducted this stu...gs of an earlier study conducted by the same team....
Other Medicine News:Health News:Estrens For Osteoporosis Might Have Adverse effects 2Health News:Complex Apnea May Explain Sleepless Nights 2Health News:Complex Apnea May Explain Sleepless Nights 3Health News:Complex Apnea May Explain Sleepless Nights 4Health News:Intake of vitamin E during pregnancy influences asthma risk in kids 2
(Date:9/4/2008)... Patient Identification for Targeted Therapies ...atment HUNTINGTON BEACH, Calif., and AMSTERDAM,...orld leader in molecular cancer diagnostics,today...gnostic test that,allows physicians to quantitativ...trogen receptor (ER), progesterone receptor (PR) a...
(Date:9/3/2008)...pt. 3 /- Simcere,Pharmaceut...nd supplier of,branded generic pharmaceuticals and...product Endu (also known as Endostar) in China,an...cal study., At the request of the SFDA, Simcere i...date the safety and therapeutic efficacy of Endu, ...
(Date:9/3/2008)...and GENEVA, Sept. 3 /- Artelis SA and... based monoclonal antibody,production with the ach...per liter. This record level was accomplished by a...high-performance stable Selexis CHO,production cel...tists at,Selexis SA using their proprietary Selexi...
(Date:9/3/2008)...erations, Updates Zingo Launch Progress and Adlea ... Conference Call Today at 11:30 am ET,...-FirstCall/ -- Anesiva,Inc. (Nasdaq: ANSV ) anno...ations to focus on commercial and late-stage produ...pecialty pharmaceutical pain management,company. T...
Breaking Medicine Technology:Agendia Launches TargetPrint(R) for Breast Cancer Patients 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Amylin Pharmaceuticals Initiates Phase 2B Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment in Obesity 1975 1Amylin Pharmaceuticals Initiates Phase 2B Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment in Obesity 1975 2Amylin Pharmaceuticals Initiates Phase 2B Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment in Obesity 1975 3Amylin Pharmaceuticals Initiates Phase 2B Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment in Obesity 1975 4Amylin Pharmaceuticals Initiates Phase 2B Dose Ranging Clinical Study of Pramlintide Metreleptin Combination Treatment in Obesity 1975 5eResearchTechnology Reports First Quarter 2008 Results 5107 1eResearchTechnology Reports First Quarter 2008 Results 5107 2eResearchTechnology Reports First Quarter 2008 Results 5107 3eResearchTechnology Reports First Quarter 2008 Results 5107 4eResearchTechnology Reports First Quarter 2008 Results 5107 5eResearchTechnology Reports First Quarter 2008 Results 5107 6eResearchTechnology Reports First Quarter 2008 Results 5107 7eResearchTechnology Reports First Quarter 2008 Results 5107 8eResearchTechnology Reports First Quarter 2008 Results 5107 9Verenium Reports Financial Results for the First Quarter 2008 5104 1Verenium Reports Financial Results for the First Quarter 2008 5104 2Verenium Reports Financial Results for the First Quarter 2008 5104 3Verenium Reports Financial Results for the First Quarter 2008 5104 4Verenium Reports Financial Results for the First Quarter 2008 5104 5Verenium Reports Financial Results for the First Quarter 2008 5104 6Verenium Reports Financial Results for the First Quarter 2008 5104 7Verenium Reports Financial Results for the First Quarter 2008 5104 8Verenium Reports Financial Results for the First Quarter 2008 5104 9Verenium Reports Financial Results for the First Quarter 2008 5104 10Verenium Reports Financial Results for the First Quarter 2008 5104 11Divigel 28R 29 28estradiol gel 29 0 1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated wit 1974 1Divigel 28R 29 28estradiol gel 29 0 1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated wit 1974 2Divigel 28R 29 28estradiol gel 29 0 1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated wit 1974 3
... no new stent thrombosis after two years in,high-r...NA, Spain, May 22, 2007,/PRNewswire-FirstCall/ -- ...-year follow-up data from its TAXUS VI clinical,tr...icacy benefits,associated with a moderate-release ...-eluting stent system -- which is not,approved for...
...up analysis shows no stent thrombosis or MACE,afte...y 22, 2007,/PRNewswire-FirstCall/ -- Boston Scient...itional data from the SPIRIT FIRST, II,and III Cli...y data,for the market-leading TAXUS(R) Express2(TM...NCE(TM) V (PROMUS(TM)) Everolimus,Eluting Coronary...
Other Medicine Technology:Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems 2SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems 3
Inquire
Adjustable speed vortex with inter-changeable heads, 110 V
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures.
...e Mo Bio Vortex Adapter in conjunction with the Vo...sing the Mo Bio Vortex Adapter is an inexpensive a...hines which offer the same technology. This parti...one time and will fit any Vortex Genie 2 with a 3 ...
Medicine Products: